RetinalGeniX Technologies

RetinalGeniX Technologies is an ophthalmic research and development company based in Petaluma, California, in the United States. Its stated mission is the prevention of blindness and the early detection and treatment of multiple systemic and ocular diseases. The company describes itself as focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies, which it intends to use both to detect ocular disease early and to identify initial physiological changes that could indicate possible future systemic disease, including neurodegenerative, cardiovascular, vascular, metabolic, and diabetic conditions. The company's technology portfolio is organized around several connected offerings. Its Pharmaco-Genetic Mapping™ platform is described as a proprietary RetinalGeniX DNA/RNA GPS™ intended to screen, monitor, profile data, and create diagnostic markers for systemic and retinal disorders. A second pillar is 24/7 remote monitoring, providing real-time physician and patient alerts through high-resolution retinal in-home and remote monitoring, described as a retinal and eye imaging system planned to be available through a wide variety of networks, locations (kiosks), and healthcare providers. A third pillar is a cost-effective, high-resolution retinal mass screening device that operates without dilation of the pupil and is aimed at ocular diseases as well as neuro-degenerative, cardiovascular, vascular, metabolic, and diabetic conditions. The company also pursues clinical drug development, seeking to enhance its portfolio of drugs and investigate alternative uses with a focus on drug validation, drug efficacy, and drug safety. RetinalGeniX frames its approach around the idea that the retina reflects the earliest changes in neuro-degenerative disease, vascular and metabolic conditions, brain function, and blindness, because the eyes are a direct extension of the brain through the optic nerve. It notes that abnormalities found within the blood vessels may signal similar changes that could eventually develop in other parts of the body, which is the rationale for using retinal imaging as a window into systemic health. The company has been listed on the OTCQB market under the ticker RTGN and has stated that a NASDAQ uplisting was planned for 2025. Its corporate progress disclosures describe a series of steps from opening its headquarters and lab in 2019, doubling its ophthalmic engineering team in 2020, obtaining a license agreement for retinal technologies and filing an S-1 in 2021, listing on the OTCQB and acquiring DNA/GPS Inc in 2022, and in 2023 receiving a patent for a Patient Home Monitoring and Physician Alert System for Ocular Anatomy, filing two preliminary drug patents (RGT 2023 and RGT 2024), and adding personnel including an interim CFO, a contract research organization, and medical and scientific advisors. In 2024 the company reported that Phase II clinical trials were underway and that a NASDAQ uplisting was planned for 2025.

RetinalGeniX Technologies is an ophthalmic research and development company headquartered in Petaluma, California, in the United States. The company's public mission is the prevention of blindness and the early detection and treatment of multiple systemic and ocular diseases. It describes itself as focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies intended to prevent blindness through the early detection and treatment of ocular diseases, and also to detect initial physiological changes that could indicate possible future systemic disease, including neurodegenerative, cardiovascular, vascular, metabolic, and diabetic conditions. The company's disclosed corporate progress provides a timeline of its development. In 2019 it opened its headquarters and laboratory. In 2020 it doubled its ophthalmic engineering team. In 2021 it obtained a license agreement for retinal technologies and filed an S-1 registration statement under the ticker OTC:RTGN. In 2022 it listed on the OTCQB market, acquired DNA/GPS Inc, added Vinay Mehindru, MD, MBA to its board of directors, and added Dr. Perich to its medical advisory board. In 2023 it was granted a patent for a Patient Home Monitoring and Physician Alert System for Ocular Anatomy, filed two preliminary patents for drugs designated RGT 2023 and RGT 2024, added Virender Ahluwalia as interim CFO, hired the contract research organization Avania, added Fred Chasalow, Ph.D. for therapeutic drug selection and development, added Herbert Gould, MD to oversee contact lens development, added Dessy Boneva, MD, FACS to its board of directors, and had its Institutional Review Board process approved. In 2024 the company reported that Phase II clinical trials were underway and that a NASDAQ uplisting was planned for 2025. The company's technology strategy is built around the premise that the retina reflects the earliest changes in neuro-degenerative disease, vascular and metabolic conditions, brain function, and blindness, because the eyes are a direct extension of the brain through the optic nerve. RetinalGeniX states that abnormalities found within the blood vessels may signal similar changes that could eventually develop in other parts of the body, which underpins its use of retinal imaging as a means of detecting systemic disease early. Its offerings include the Pharmaco-Genetic Mapping™ platform, described as a proprietary RetinalGeniX DNA/RNA GPS™ to screen, monitor, profile data, and create diagnostic markers for systemic and retinal disorders; a 24/7 remote monitoring capability providing real-time physician and patient alerts through high-resolution retinal in-home and remote monitoring, planned to be available through a wide variety of networks, locations (kiosks), and healthcare providers; a cost-effective high-resolution retinal mass screening device that operates without dilation of the pupil for ocular diseases and for neuro-degenerative, cardiovascular, vascular, metabolic, and diabetic conditions; and clinical drug development activities aimed at enhancing its portfolio of drugs and investigating alternative uses, with a focus on drug validation, drug efficacy, and drug safety. The company has been listed on the OTCQB market under the ticker RTGN and has stated that a NASDAQ uplisting was planned for 2025. It is based in Petaluma, California.

• Opened headquarters and lab

• Doubled ophthalmic engineering team

• Obtained license agreement for retinal technologies; filed S-1 (OTC:RTGN)

• Listed on the OTCQB market; acquired DNA/GPS Inc; added Vinay Mehindru, MD, MBA to board; added Dr. Perich to medical advisory board

• Patent granted for Patient Home Monitoring and Physician Alert System for Ocular Anatomy; filed two preliminary drug patents (RGT 2023 and RGT 2024); added Virender Ahluwalia as interim CFO; hired CRO Avania; added Fred Chasalow, Ph.D.; added Herbert Gould, MD; added Dessy Boneva, MD, FACS to board; Institutional Review Board process approved

• Phase II clinical trials underway; NASDAQ uplisting planned for 2025

An ophthalmic research and development company using high-resolution retinal imaging and pharmaco-genetic mapping to enable early detection of ocular and systemic diseases, with a mission of blindness prevention.

• Pharmaco-Genetic Mapping™

  Proprietary RetinalGeniX DNA/RNA GPS™ to screen, monitor, profile data, and create diagnostic markers for systemic and retinal disorders.

• 24/7 Remote Monitoring

  24/7 real-time physician and patient alert; high-resolution retinal in-home and remote monitoring (retinal and eye imaging system), planned to be available through a wide variety of networks, locations (kiosks) and healthcare providers.

• High-Resolution Retinal Mass Screening Device

  Cost-effective high-resolution retinal mass screening device without dilation of the pupil for ocular diseases, neuro-degenerative disorders, cardiovascular, vascular, metabolic, and diabetes.

• Clinical Drug Development

  Enhancing the portfolio of drugs and investigating alternative uses with focuses on drug validation, drug efficacy and drug safety.

1. 1RetinalGeniXretinalgenix.com
2. 2About & Mission – RetinalGeniXretinalgenix.com
3. 3RetinalGeniX Technologies (United States) – Wikidatawikidata.org